BERLIN (dpa-AFX) - Merck KGaA (MKGAY.PK) announced that it presented new efficacy data for investigational Cladribine Tablets in two oral presentations at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) taking place September 14-17, 2016, in London.
The findings, from the phase III CLARITY and CLARITY EXTENSION trials and from the open-label maintenance period of the phase III ORACLE-MS study, demonstrated durable efficacy of Cladribine Tablets in patients with multiple sclerosis (MS) along with a well-characterized safety profile.
CLARITY and CLARITY EXTENSION studies confirmed that 20 days of oral dosing over two years was effective in reducing the frequency of relapses and slowing disability progression for up to four years.
Copyright RTT News/dpa-AFX
© 2016 AFX News
